Charles Stacey, MBBS, MRCS, MBA

Dr. Stacey is president and chief executive officer of Cerecin, a clinical-stage biotechnology company developing a platform of ketogenic compounds to treat neurological diseases.  Prior to joining Cerecin, he was with Inventages, a global life science venture capital group, with $1.5 billion under management. At Inventages, he focused on investments in neurology.

Before his tenure with Inventages, Dr. Stacey ran a medical device company and worked for a number of early-stage healthcare companies. He currently serves on the board of governors of the Accreditation Council for Medical Affairs (ACMA).

He received his medical degree from King’s College London and practiced as a trauma and reconstructive surgeon. Dr. Stacey completed an MBA at the London Business School and the Wharton School.  His original undergraduate degree and research were in neuroscience at UCL/Queen Square.